ArticleJournal of cancer research and clinical oncology2020
Gastric cancer in young patients: a separate entity with aggressive features and poor prognosis.
Article in Journal of cancer research and clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 37 citations in OpenAlex.
- Defining a Nomogram for Predicting Early Recurrence in Gastric Cancer Patients After Neoadjuvant Chemotherapy and Radical Gastrectomy.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2023Trial
- Early-Onset Gastric Cancer as a High-Risk Disease Entity in the United States: Clinicopathologic Features, Regional Variation, and Outcomes.Cancer medicine · 2026Article
- Telisotuzumab Adizutecan (ABBV-400), a Novel c-Met-Targeting Antibody-Drug Conjugate: First-in-Human Results in Advanced Gastric/Gastroesophageal Junction Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Real-world insights into young-onset gastroesophageal adenocarcinoma: an all-Ireland population-based cancer registry analysis.ESMO gastrointestinal oncology · 2026Article
- Early population-level impact of Helicobacter pylori eradication on gastric cancer mortality in Japan: a counterfactual analysis of short-term divergence.Population health metrics · 2026Article
- Diagnostic and therapeutic challenges in claudin 18.2-positive gastric cancer treated with zolbetuximab: Intrapatient heterogeneity or secondary loss of expression?Journal of cancer research and clinical oncology · 2026Article
- Accelerated aging mediates the association between fecal incontinence and mortality: Evidence from the National Health and Nutrition Examination Survey.The Journal of international medical research · 2026Article
- Early onset gastrointestinal cancers - a needs analysis.Frontiers in oncology · 2026Article
- Age-Stratified Clinicopathological Features and Efficacy of Adjuvant Chemotherapy in Resectable Gastric Cancer: An East-West Population-Based Study.Current oncology (Toronto, Ont.) · 2025Article
- Proposal of age definition for early-onset gastric cancer based on the Korean Gastric Cancer Association nationwide survey data: a retrospective observational study.Annals of surgical treatment and research · 2025Article
- Clinical and molecular implications of sex differences in surgically treated early-onset gastric cancer.Gastroenterology report · 2025Article
- Early onset gastric cancer: clinical and molecular insights into a rising epidemic among younger adults.Proceedings (Baylor University. Medical Center) · 2025Article
- Immune checkpoint inhibitors plus chemotherapy in the first-line treatment of young unresectable gastric cancer patients: a multicentre real-world study.Frontiers in oncology · 2025Article
- Prognostic analysis of systemic antitumor therapy in young patients with advanced liver cancer: A cohort study.Oncology letters · 2024Article
- Machine learning methods predict recurrence of pN3b gastric cancer after radical resection.Translational cancer research · 2024Article
- Metastasis patterns and prognosis in young gastric cancer patients: A propensity score‑matched SEER database analysis.PloS one · 2024Article
- Efficacy and safety of chemotherapy in young patients with advanced gastroesophageal adenocarcinoma: data from the Spanish AGAMENON-SEOM registry.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2024Article
- Predictive Factors Associated with Survival in Female Gastric Cancer Patients in Southeast Asia.Women's health reports (New Rochelle, N.Y.) · 2024Article
- Latin American young patients with gastric adenocarcinoma: worst prognosis and outcomes.Journal of gastrointestinal oncology · 2023Article
- Oncological prognosis and morbidity of hepatectomy in elderly patients with hepatocellular carcinoma: a propensity score matching and multicentre study.BMC surgery · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
purposeTo investigate the clinicopathological features and survival outcomes between young and old patients with gastric cancer (GC), and further determine the role of young age in the prognosis of GC.
methodsPatients with stage I-III gastric adenocarcinomas undergoing curative surgery were enrolled, divided into young (aged 18-49 years, YG), middle-aged (50-59 years, MG), and old (≥ 60 years, OG) groups. Exclusion criteria were neoadjuvant therapy and history of malignant tumors. Clinicopathological features, overall survival (OS), disease-free survival (DFS), and recurrence patterns were compared among three groups.
results1131 patients were finally included, with 270, 314, and 547 cases in the YG, MG, and OG, respectively. Compared to others, YG had higher proportion of female, middle-third gastric cancer, poor differentiation, N3b stage, and adjuvant chemotherapy. YG demonstrated poorer 5-year OS than MG (62.4% vs. 70.8%, P = 0.019), but better than OG (62.4% vs. 58.7%, P = 0.031). YG also suffered inferior 5-year DFS (75.2% vs. 82.8%, P = 0.040) compared with MG, and higher incidence of peritoneal recurrence than MG (15.1% vs. 5.2%, P < 0.001) and OG (15.1% vs. 4.1%, P < 0.001). Multivariate analysis identified young age as the independent prognostic factor for OS [hazard ratio (HR) = 1.347, 95% CI 1.018-1.781, P = 0.037], DFS (HR = 1.601, 95% CI 1.079-2.376, P = 0.019), and peritoneal recurrence (HR = 2.936, 95% CI 1.505-5.726, P = 0.002).
conclusionsYoung GC patients demonstrated aggressive features with poor prognosis and enhanced management may be warranted for this subgroup.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.